Scintigraphic imaging of breast tumors

European Journal of Radiology

Volumn 24, Issue 1, 1997, Pages 2-10

  Maublant, Jean ^a  

^a CENTRE JEAN PERRIN   (France)

Author keywords

breast; breast neoplasms; deoxyglucose; fluorine radioisotopes; mammary neoplasms; multiple drug resistance; P glycoprotein; somatostatin receptors; technetium Tc 99m sestamibi; thallium radioisotopes

Indexed keywords

ESTRADIOL; FLUORODEOXYGLUCOSE F 18; IODINE 125; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PENTETREOTIDE IN 111; THALLIUM 201;

ADULT; AGED; BREAST CANCER; CANCER SCINTISCANNING; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

EID: 0031057436     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0720-048X(96)01111-4     Document Type: Article

References (56)

1. [1] Low-Beer BVA. Surface measurements of radioactive phosphorus in breast tumors as possible diagnostic method. Science 1946; 104: 399.
2. [2] Cox PH, Belfer AJ, Van der Pompe WB. Thallium-201 chloride uptake in tumors, a possible complication in heart scintigraphy. Br J Radiol 1976; 49: 767-768.
3. [3] Hisada K, Tonami H, Miyamae T, Hiraki Y, Yamazaki T, Maeda T, Nakajo M. Clinical evaluation of tumor imaging with thallium-201 chloride. Radiology 1978; 129: 497-500.
4. [4] Sehweil A, McKillop JH, Ziada G, Al-Sayed M, Abdel-Dayem H, Omar YT. The optimum time for tumor imaging with thallium-201. Eur J Nucl Med 1988; 13: 527-529.
5. [5] Waxman A, Ramanna L, Memsic L, Foster CE, Silberman AW, Gleischman SH, Brenner RJ, Brachman MB, Kuhar CJ, Yadegar J. Thallium scintigraphy in the evaluation of mass abnormalities of the breast. J Nucl Med 1993; 34: 18-23.
6. [6] Lee VW, Sax EJ, McAneny DB, Pollack S, Blanchard RA, Beazley RM, Kavanah MT, Ward RJ. A complementary role for thallium-201 scintigraphy with mammography in the diagnosis of breast cancer. J Nucl Med 1993; 34: 2095-2100.
7. [7] Cimitan M, Volpe R, Candiani E, Gusso G, Ruffo R, Borsatti E, Massarut S, Rossi C, Morassut S, Carbone A. The use of thallium-201 in the preoperative detection of breast cancer: an adjunct to mammography and ultrasonography. Eur J Nucl Med 1995; 22: 1110-1117.
8. [8] Ito Y, Murankka A, Harada T, Matsudo A, Yokobayashi T, Terashima H. Experimental study on tumor affinity of T1-201. Eur J Nucl Med 1978; 3: 81-86.
9. [9] Ando A, Ando I, Katayama M, Sanada S, Hiraki T, Mori H, Tonami N, Hisada K. Biodistributions of radioactive alkaline metals in tumor bearing animals: comparison with T1-201. Eur J Nucl Med 1988; 14: 352-357.
10. [10] Sehweil AM, McKillop JH, Milrov R, Wilson R, Abdel-Dayem HM, Omar YT. Mechanism of T1-201 uptake in tumours. Eur J Nucl Med 1989; 15: 376-379.
11. [11] Muller ST, Guth-Tougelids B, Creutizig H. Imaging of malignant tumors with Tc-99m MIBI SPECT. Eur J Nucl Med 1987; 28: 562 (abstract).
12. [12] Campeau RJ, Kronemer KA, Sutherland CM. Concordant uptake of Tc-99m sestamibi and T1-201 in unsuspected breast tumor. Clin Nucl Med 1992; 17: 936-937.
13. [13] Atkolun C, Bayhan H, Kir M. Clinical experience with Tc-99m MIBI in patients with malignant tumors: preliminary results and comparison with T1-201. Clin Nucl Med 1992; 17: 171-176.
14. [14] Khalkhali I, Mena I, Jouanne E, Diggles L, Jackson B, Klein S. Breast cancer detection with Tc-99m-sestamibi prone imaging: its correlation with mammography and pathology. Clin Nucl Med 1992; 9: 761 (abstract).
15. [15] Azaloux H, Baudin J, Chanol MA, Boisseron D, Lefebur S, Kerjean J, Escarmant P, Lemab G, Moretti JL, Vilcoq JR. Scintigraphie du cancer du sein au mibi-Tc-99m. Facteur pronostic? Méd Nucl 1993; 18: 319 (abstract).
16. [16] de Maesschalck P, Demonceau G. Intérêt du Tc-MIBI dans la détection du cancer du sein. Méd Nucl 1993; 18: 324 (abstract).
17. [17] Khalkhali I, Mena I, Jouanne E, Diggles L, Venegas R, Block J, Alle K, Klein S. Prone scintimammography in patients with suspicion of carcinoma of the breast. J Am Coll Surg 1994; 178: 491-497.
18. [18] Khalkhali I, Cutrone, Diggles L, Venegas R, Vargas H, Jackson B, Klein S. Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. J Nucl Med 1995; 36: 1784-1789.
19. [19] Khalkhali I, Cutrone JA, Mena I, Diggles LE, Venegas RI, Vargas HI, Jackson BL, Khalkhali S, Moss JF, Klein S, Scintimammography: the complementary role of Tc-99m-sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995; 196: 421-426.
20. [20] Kao CH, Wang SJ, Lin TJ. The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med 1994; 21: 432-436.
21. [21] Burak Z, Argon M, Memis A, Erdem S, Balkan Z, Duman Y, Ustun EE, Erhan Y, Ozkilic H. Evaluation of palpable breast masses with Tc-99m-MIBI: a comparative study with mammography and ultrasonography. Nucl Med Comm 1994; 15: 604-612.
22. [22] Scopinaro F, Schillaci O, Scarpini M, Mingazzini PL, DiMacio L, Banci M, Danielli R, Zerilli M, Limiti MR, Colella AC. Technetium-99m sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med 1994; 21: 984-987.
23. [23] Taillefer R, Robidoux A, Lambert R, Turpin S, Laperrière J. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 1995; 36: 1758-1765.
24. [24] Khalkhali I, Villanueva-Meyer J, Edell SL, Hanelin LG, Lugo CE, Taillefer R, Freeman LM, Neal CE, Scheff AM, Connolly JL, Schnitt SJ, Baum JK, Houlihan MJ, Hale CA, Haber SB. Diagnostic accuracy of Tc-99m-sestamibi breast imaging in breast cancer detection. J Nucl Med 1996; 37: 74P (abstract).
25. [25] Maurer AH, Caroline DF, Jadali FJ, Manzone TA, Maier WP, Au FC, Schnall SF. Limitations of craniocaudal thallium-201 and technetium-99m-sestamibi mammoscintigraphy. J Nucl Med 1995; 36: 1696-1700.
26. [26] Khalkhali I, Villanueva-Meyer J, Edell SL, Hanelin LG, Lugo CE, Taillefer R, Freeman LM, Neal CE, Scheff AM, Connolly JL, Schnitt SJ, Baum JK, Houlihan MJ, Hale CA, Haber SB. Impact of breast density on the diagnostic accuracy of Tc-99m-sestamibi breast imaging in the detection of breast cancer. J Nucl Med 1996; 37: 74P-75P (abstract).
27. [27] Maublant J, de Latour M, Mestas D, Clemenson A, Charrier S, Feillel V, Le Boudec G, Kaufmann P, Dauplat J, Veyre A. Tc-99m-sestamibi uptake in breast tumors and associated lymph nodes uptake. J Nucl Med 1996; 37: 922-925.
28. [28] Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis-(2-methoxyisobutylisonitrile) technetium (I) in cultured mouse fibroblasts. J Nucl Med 1990; 31: 1646-1653.
29. [29] Crane P. Laliberté R, Heminway S, Thoolen M, Orlandi C. Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention. Eur J Nucl Med 1993; 20: 20-25.
30. [30] Backus M, Piwnica-Worms D, Hockett D, Kronauge J, Lieberman M, Ingram P, LeFurgey A. Microprobe analysis of Tc-MIBI in heart cells: Calculation of mitochondrial membrane potential. Am J Physiol 1993; 265: C178-C187.
31. [31] Davis S, Weiss MJ, Wong JR, Lampidis TJ, Chen LB. Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J Biol Chem 1985; 260: 13844-13850.
32. [32] Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, Holman BL. Uptake of the cation hexakis (2-methoxyisobutyl-isonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990; 50: 2198-2202.
33. [33] Maublant J, Zhang Z, Rapp M, Ollier M, Michelot J, Veyre A. In vitro uptake of technetium-99m teboroxime in carcinoma cell lines and normal cells: comparison with technetium-99m-sestamibi and thallium-201. J Nucl Med 1993; 34: 1949-1952.
34. [34] Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977-984.
35. [35] Cordobes MD, Starzec A, Delmon-Moingeon L, Blanchot C, Kouyoumdjian JC, Prévost G, Caglar M, Moretti JL. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. J Nucl Med 1996; 37: 286-289.
36. [36] Ballinger JR, Hua HA, Berry BW, Firby P, Boxen I. Tc-99m-sestamibi as an agent for imaging P-glycoprotein-mediated multidrug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Commun 1995; 16 (4): 253-257.
37. [37] Kabasakal L, Ozker K, Hayward M, Akansel G, Griffith O, Isitman AT, Hellman R, Collier D. Technctium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance. Eur J Nucl Med 1996; 23: 568-570.
38. [38] Sandor VA, Robey R, Alverez M et al. Rhodamine efflux and anthracycline resistance by a non-Pgp and non-MRP mechanism in a selected breast cancer cell line. Proc ASCR 1996; 37: 320 (abstract).
39. [39] Rambaldi PF, Mansi L, Procaccini E, Di Gregorio F, Del Vecchio E. Breast cancer detection with Tc-99m tetrofosmin. Clin Nucl Med 1995; 20: 703-705.
40. [40] Piccolo S, Lastoria S, Mainolfi C, Muto P, Bazzicalupo L, Salvatore M. Technetium-99m-methylene diphosphonate scintimammography to image primary breast cancel. J Nucl Med 1995; 36: 718-724.
41. [41] Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer 1993; 72: 2979-2985.
42. [42] Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995; 36: 1625-1632.
43. [43] Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972-1980.
44. [44] Kubota K, Matsuzwana T, Amemiya A, Kondo M, Fujiwara T, Watanuki S, Ito M, Ido T. Imaging of breast cancer with (F-18)-fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 1989; 13: 1097-1098.
45. [45] Wahl RL, Cody R, Hutchins G, Mudgett E. Positron emission tomographic scanning of primary and the metastatic breast carcinoma with radiolabeled glucose analog 2-deoxy-F-18-fluoro-d-glucose. N Engl J Med 1991; 324: 200.
46. [46] Wahl RL, Cody R, Hutchins G, Mudgett E. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analog 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179: 765-770.
47. [47] Tse NY, Hoh CK, Hawkins RA, Zinner MJ, Dahlbom M, Choi Y, Maddahi J, Brunicardi FC, Phelps ME, Glaspy JA. The application of PET imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992; 216: 27-34.
48. [48] Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE, Hortobagyi GN, Tilbury RS. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71: 3920-3925.
49. [49] Adler LA, Corwe JP, Al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18]-2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187: 743-750.
50. [50] Crowe JP, Adler LP, Shenk RR, Sunshine J. Positron emission tomography and breast masses; comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994; 1(2): 132-140.
51. [51] Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11: 2101-2111.
52. [52] Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, Katzenellenbogen JA, Breast cancer: PET imaging of estrogen receptors. Radiology 1988; 169: 45-48.
53. [53] Dehdashti F, McGuire AH, Van Brocklin HF, Siegel BA, Andriole DP, Griffeth LK, Pomper MG, Katzenellenbogen JA, Welch MJ. Assessment of 21-[F-18]fluoro-16α-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med 1991; 32: 1532-1537.
54. [54] John CS, Vilner BJ, Gulden ME, Efange SMN, Langason RB, Moody TW, Bowen WD. Synthesis and pharmacological characterization of 4-[I-125]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide: a high affinity σ receptor ligand for potential imaging of breast cancer. Cancer Res 1995; 55: 3022-3027.
55. [55] Bakir MA, Eccles SA, Babich JW, Aftab N, Styles JM, Dean CJ, Ott RJ. c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J Nucl Med 1992; 33: 2154-2160.
56. [56] van Eijck CH, Krenning EP, Bootsma A, Oei HY, van Pel R, Lindemans J, Jeekel J, Reubi JC, Lamberts SW. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 1994; 343: 640-643.